{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:56:49Z","timestamp":1789880209078,"version":"4.0.1"},"reference-count":42,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1586\/ecp.09.7","type":"journal-article","created":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T06:48:20Z","timestamp":1241592500000},"page":"231-238","source":"Crossref","is-referenced-by-count":20,"title":["Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications"],"prefix":"10.1586","volume":"2","author":[{"given":"Gerhard","family":"Rammes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1358\/dnp.1998.11.9.863689","volume":"11","author":"Parsons","year":"1998","journal-title":"Drug News Perspect."},{"key":"CIT0002","first-page":"261","volume":"8","author":"Danysz","year":"1995","journal-title":"Drug News Perspect."},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0920-1211(91)90095-W","volume":"10","author":"Meldrum","year":"1991","journal-title":"Epilepsy Res."},{"key":"CIT0004","unstructured":"Parsons CG, Danysz W, Zieglg\u00e4nsberger W. Excitatory amino acid neurotransmission. In:\n                      Handbook of Experimental Pharmacology\n                      , Springer-Verlag, Heidelberg, Germany 249\u2013303 (2005)."},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0165-6147(90)90323-Z","volume":"11","author":"Lodge","year":"1990","journal-title":"Trends Pharmacol. Sci."},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neuron.2004.09.012","volume":"44","author":"Malenka","year":"2004","journal-title":"Neuron"},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2174\/156800705774322021","volume":"4","author":"Koch","year":"2005","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"CIT0010","doi-asserted-by":"crossref","first-page":"S381","DOI":"10.1017\/S1461145704004845","volume":"7","author":"Tariot","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"CIT0011","first-page":"160","volume":"10","author":"Reisberg","year":"2003","journal-title":"Eur. J. Neurol."},{"key":"CIT0012","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0028-3908(98)00161-0","volume":"38","author":"Parsons","year":"1999","journal-title":"Neuropharmacology"},{"key":"CIT0013","unstructured":"Gilling K, Jatzke C, Hechenberger M, Denk S, Parsons CG. Effects of memantine and neramexane on human NMDA receptors from post mortem cortical tissue and in patch clamp experiments from cloned receptors. Presented at:\n                      36th Society for Neuroscience Annual Meeting\n                      . Atlanta, GA, USA 14\u201318 October 2006."},{"key":"CIT0015","unstructured":"Parsons CG. New developments in glutamate pharmacology. Presented at:\n                      BC\u2019s Second Annual Conference\n                      , Orlando, FL, USA 4\u20135 March 1999. Report in:\n                      IDrugs\n                      12, 29\u201336 (1999)."},{"key":"CIT0016","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/sj.npp.1300657","volume":"30","author":"Bachteler","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"CIT0017","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1124\/jpet.106.103697","volume":"318","author":"Kos","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2005.07.003","volume":"519","author":"Malyshkin","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"CIT0019","unstructured":"Suckf\u00fcll M, Jastreboff P, Wirth Y\n                      et al.\n                      Neramexane, a novel receptor antagonist with a dual mode of action, for oral administration in patients with objective tinnitus.\n                      Annual Meetings of the American Academy of Otolaryngology \u2013 Head and Neck Surgery\n                      , San Diego, CA, USA, 4\u20137 October 2009."},{"key":"CIT0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2174\/1381612024607117","volume":"8","author":"Danysz","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s007260070044","volume":"19","author":"Parsons","year":"2000","journal-title":"Amino Acids"},{"key":"CIT0022","unstructured":"Parsons CG, Gilling KE, Rammes G\n                      et al.\n                      Effects of neramexane on ionotropic \u03b19\/\u03b110 nicotinic receptors and human NMDA (NR1\/NR2A) \u2013 relevance for tinnitus.\n                      Annual Meetings of the American Academy of Otolaryngology \u2013 Head and Neck Surgery\n                      , San Diego, CA, USA, 4\u20137 October 2009."},{"key":"CIT0023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejphar.2007.03.026","volume":"566","author":"Plazas","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"CIT0024","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","volume":"306","author":"Rammes","year":"2001","journal-title":"Neurosci. Lett."},{"key":"CIT0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s002109900056","volume":"360","author":"Hesselink","year":"1999","journal-title":"Naunyn Schmiedebergs Arc. Pharmacol."},{"key":"CIT0026","first-page":"153","volume":"29","author":"Brown","year":"2003","journal-title":"Abstr. Soc. Neurosci."},{"key":"CIT0027","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(98)00112-5","volume":"347","author":"Wenk","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"CIT0028","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0006-8993(00)02078-3","volume":"862","author":"Liu","year":"2000","journal-title":"Brain Res."},{"key":"CIT0029","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0304-3940(00)00829-6","volume":"281","author":"Sopala","year":"2000","journal-title":"Neurosci. Lett."},{"key":"CIT0030","unstructured":"Frankiewicz T, Parsons CG. The uncompetitive NMDA receptor antagonist MRZ 2\/579 and memantine have a similar\n                      in vitro\n                      \u2013 TI: LTP and hypoxic\/hypoglycaemic excitotoxicity in hippocampal slices. Presented at:\n                      29th Society for Neuroscience Meeting\n                      . Miami Beach, FL, USA, 23\u201328 October 1999."},{"key":"CIT0031","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","volume":"48","author":"Greenamyre","year":"1991","journal-title":"Arch. Neurol."},{"key":"CIT0032","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1523\/JNEUROSCI.16-04-01561.1996","volume":"16","author":"Kretschmer","year":"1996","journal-title":"J. Neurosci."},{"key":"CIT0033","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0028-3908(98)00165-8","volume":"38","author":"Karcz-Kubicha","year":"1999","journal-title":"Neuropharmacology"},{"key":"CIT0034","unstructured":"Danysz W, Lorenz B, Karcz-Kubicha M. Effect of uncompetitive NMDA receptor antagonists on motor fluctuations produced by chronic l-DOPA treatment in two animal models. Presented at:\n                      30th Society for Neuroscience Meeting\n                      . New Orleans, USA (2000)."},{"key":"CIT0035","first-page":"R132","volume":"361","author":"Tillner","year":"2000","journal-title":"Arch. Pharmacol."},{"key":"CIT0036","unstructured":"Goldman Sachs Global Healthcare.\n                      Goldman Sachs Global Healthcare Conference Forest Laboratories Inc., Company Presentation\n                      (2006)."},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejpain.2007.02.002","volume":"12","author":"Klein","year":"2008","journal-title":"Eur. J. Pain (Lond.)"},{"key":"CIT0038","unstructured":"Mucke H. HAM IDDB Meeting Report. Presented at: German\n                      Society for Addiction Research and Therapy \u2013 14th Annual Meeting\n                      . Berlin, Germany (2002)."},{"key":"CIT0039","first-page":"S04","author":"Wiesbeck","year":"2003","journal-title":"ESBRA"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1996.tb15245.x"},{"key":"CIT0044","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.neuropharm.2005.01.002","volume":"48","author":"Vengeliene","year":"2005","journal-title":"Neuropharmacology"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2007.164.3.519"},{"key":"CIT0046","first-page":"S37","volume":"18","author":"Alam","year":"2007","journal-title":"Behav. Pharmacol."}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/ecp.09.7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,19]],"date-time":"2019-05-19T18:04:38Z","timestamp":1558289078000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/ecp.09.7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,1,10]]},"published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.1586\/ecp.09.7"],"URL":"https:\/\/doi.org\/10.1586\/ecp.09.7","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}